earnings
confidence high
sentiment neutral
materiality 0.55
Mineralys reports Q2 net loss $41M; Advance-HTN trial ~90% enrolled, on track for Q1 2025 data
Mineralys Therapeutics, Inc.
2024-Q2 EPS reported
-$1.54
- Net loss of $41.0M for Q2 2024 vs $12.1M in Q2 2023; cash and investments of $311.1M as of June 30, 2024.
- Advance-HTN pivotal trial ~90% enrolled; topline data expected Q1 2025 after FDA alignment on primary endpoint.
- Launch-HTN Phase 3 enrollment ahead of schedule; topline data on track for 2H 2025.
- Explore-CKD Phase 2 trial enrollment ramping; topline data expected 1H 2025.
- Cash runway into 2026 covers planned clinical studies and corporate operations.